---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Heterogeneity of treatment effect"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Heterogeneity of treatment effect. Topics: BOND-003 Cohort C: tumor pattern and prior therapy at study entry, BOND-003 Cohort C: complete response in second-line and chemotherapy-pretreated subgroups, BOND-003 Cohort C: subgroup consistency and response after re-induction, BOND-003 Cohort C: cystectomy-free survival across subgroups, and 5 further topics. 9 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### BOND-003 Cohort C: tumor pattern and prior therapy at study entry

| Baseline characteristic | n | % |
| --- | --- | --- |
| CIS with high-grade Ta/T1 | “22” | “19.6” |
| CIS alone | “90” | “80.4” |
| At least one prior therapy other than BCG | “53” | “47.3” |
| Serial adjuvant chemotherapy | “34” | “30.4” |
| Systemic immunotherapy | “7” | “6.3” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-2.2.2.3-2"></a>

### BOND-003 Cohort C: complete response in second-line and chemotherapy-pretreated subgroups

> “Median follow-up: 25.8 months; CR rate at any time: 75.5% (83/110)”
> “23/110 (21%) patients: Second-Line BCG-UR”
> “CR rate at any time: 69.6% (16/23)”
> “34/110 (31%) patients Prior Intervening Chemotherapy, with”
> “CR rate at any time: 64.7% (22/34)”
> “Second-Line: patients diagnosed with BCG-UR who received an additional therapy after adequate BCG.”
> “Prior Intervening Chemotherapy: adjuvant IVE chemotherapy before or after adequate BCG.”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="topic-2.2.2.3-3"></a>

### BOND-003 Cohort C: subgroup consistency and response after re-induction

> “High CR Rate Consistent Across Patient Subgroups, Including Patients Treated with Prior Chemotherapy”
> “50.0% of patients reinduced with oncolytic immunotherapy converted to CR”
> “64.3% remain in durable response after conversion to CR”

Source: [Tyson (2025a)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_C_Late-Breaking_Plenary.pdf)

<a id="topic-2.2.2.3-4"></a>

### BOND-003 Cohort C: cystectomy-free survival across subgroups

> “Median CFS not reached in the efficacy analysis set or any subgroups”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-2.2.2.3-5"></a>

### Comparator trial: TAR-200 by presence of papillary disease and T stage

> “Subgroup analyses showed consistently high CR rates across all clinically relevant subgroups, including patients with and without concurrent papillary disease (82.1% and 82.5%, respectively; Data Supplement, Fig S2).”
> “Twelve-month DFS rates were consistent in patients with high-grade Ta and T1 disease (70.0% [95% CI, 44.8 to 85.4] and 72.2% [95% CI, 44.8 to 87.6], respectively).”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.3-6"></a>

### Comparator trials: carcinoma in situ cohorts and papillary-only cohorts

> “Five-year follow-up data from this trial found an estimated HG RFS at 57 months of 13% in the CIS cohort, and 33% in the Ta/T1 cohort.”
> “Cystectomy-free survival at month 60 was 49% (43% in the CIS cohort and 59% in the Ta/T1 cohort)”
> “In cohort A (patients with CIS with or without Ta/T1 papillary disease), pembrolizumab monotherapy achieved a 41% CRR at three months”
> “In cohort B (patients with Ta/T1 papillary disease without CIS), the 12-month DFS was 43.5%”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.3-7"></a>

### Systematic reviews: predictors of response after BCG failure

> “A higher number of previous BCG courses, BCG refractory/unresponsive or CIS predicted lower response rates.”
> “The pooled 12-month response rates were 24% for trials with > 2 prior BCG courses and 36% for those with > 1 BCG courses.”
> “Initial response rate did not predict durable responses highlighting the need for longer-term follow-up.”
> “showed that patients with papillary-only recurrences appeared more effectively treated (median recurrence free rate of 44% at one year, median progression-free rate of 89% at a median follow-up of 19 months)”
> “(median CRR of 17% at one year with a median progression-free rate of 95% at a median follow-up of 12 months), highlighting potential biological differences between these two tumour entities which should be analysed separately when reporting results of clinical trials”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.3-8"></a>

### Regulatory guidance on stratification by tumor pattern

> “Sponsors should stratify the randomization and analysis of trials that include patients”
> “with CIS based on the type of disease (CIS alone or CIS with resected papillary disease)”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-2.2.2.3-9"></a>

### Variable enrollment criteria across BCG-unresponsive trials

> “Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.”
> “The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.”
> “For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.”

Source: [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
